Literature DB >> 24355007

Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.

Y Nozawa1, T Umemura, Y Katsuyama, S Shibata, T Kimura, S Morita, S Joshita, M Komatsu, A Matsumoto, K Yoshizawa, M Ota, E Tanaka.   

Abstract

A genetic polymorphism of the newly discovered interferon-λ 4 (IFNL4) gene was associated with hepatitis C virus (HCV) clearance in individuals of African ancestry. To assess whether a dinucleotide variant of IFNL4 (ss469415590) also affected treatment outcome of antiviral therapy in Japan, we genotyped 213 patients with chronic genotype 1 HCV infection and 176 healthy subjects. The ΔG allele was associated with treatment failure [odds ratio (OR) 4.73, P = 0.019], as was the IFL3 rs8099917 single nucleotide polymorphism (SNP) (OR 5.06, P = 0.068). The correlation between ss469415590 and rs8099917 was high (r(2)  = 0.92, D' = 0.98). Multivariate analysis revealed that the rs8099917 SNP was independently associated with treatment failure (OR 5.28, P = 0.009). Therefore, ss469415590 may be another predictive marker of antiviral therapy outcome in the Japanese population.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL28B; hepatitis C virus; interferon-λ 4; pegylated interferon

Mesh:

Substances:

Year:  2014        PMID: 24355007     DOI: 10.1111/tan.12264

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  4 in total

1.  IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.

Authors:  Tatsuo Miyamura; Tatsuo Kanda; Shingo Nakamoto; Makoto Arai; Masato Nakamura; Shuang Wu; Xia Jiang; Reina Sasaki; Yuki Haga; Shin Yasui; Yoshihiko Ooka; Tetsuhiro Chiba; Fumio Imazeki; Shigeru Mikami; Osamu Yokosuka
Journal:  Int J Hepatol       Date:  2014-12-08

2.  Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population.

Authors:  Peng Huang; Yinan Yao; Ming Yue; Ting Tian; Hongbo Chen; Mingzhu Chen; Jie Wang; Yun Zhang; Rongbin Yu
Journal:  Sci Rep       Date:  2017-02-10       Impact factor: 4.379

3.  IL28B polymorphisms and clinical implications for hepatitis C virus infection in Uzbekistan.

Authors:  Dinara Khudayberganova; Masaya Sugiyama; Naohiko Masaki; Nao Nishida; Motokazu Mukaide; Dildora Sekler; Renat Latipov; Kan Nataliya; Suyarkulova Dildora; Said Sharapov; Guzal Usmanova; Mahmarajab Raxmanov; Erkin Musabaev; Masashi Mizokami
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

4.  KIR, HLA, and IL28B variant predict response to antiviral therapy in genotype 1 chronic hepatitis C patients in Japan.

Authors:  Yuichi Nozawa; Takeji Umemura; Satoru Joshita; Yoshihiko Katsuyama; Soichiro Shibata; Takefumi Kimura; Susumu Morita; Michiharu Komatsu; Akihiro Matsumoto; Eiji Tanaka; Masao Ota
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.